Life Technologies said last month that its SOLiD platform is "supporting" the Genomax project of the University of Strasbourg, France, to study diseases such as diabetes, obesity, asthma, and arterial hypertension.
Genomax, funded with €1.1 million ($1.4 million) from the University of Strasbourg, the regional government, and others, is part of Biomax, a translational biobank project to enable the storage and analysis of thousands of human samples.
According to Seiamak Bahram, head of Genomax and a professor of immunology at Strasbourg University Hospital, "hundreds" of blood samples have been sequenced on the SOLiD platform, providing "an invaluable insight into the most common diseases."
Life Tech's director of digital PCR in Europe, Herve Pouzoullic, said in a statement that the company "is proud to be supplying" its products to Genomax, including its SOLiD sequencing and Open Array Real-Time PCR platforms.